Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: RNA interference-based technology - Alnylam

Drug Profile

Research programme: RNA interference-based technology - Alnylam

Alternative Names: KC2; MC3; MC3 LNP; MD1; reLNP

Latest Information Update: 11 Nov 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Alnylam Pharmaceuticals
  • Developer AlCana Technologies; Alnylam Pharmaceuticals; Icahn School of Medicine at Mount Sinai; Massachusetts General Hospital; Massachusetts Institute of Technology; University of Bonn; University of British Columbia
  • Class Small interfering RNA
  • Mechanism of Action CCR2 receptor antagonists; Claudin 3 inhibitors; DNA-directed RNA polymerase inhibitors; RNA interference; TOR1A protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • No development reported Autoimmune disorders; Cancer; Dystonia; Inflammation; Influenza A virus infections

Most Recent Events

  • 17 Jan 2013 No development reported - Preclinical for Cancer in Germany (Parenteral)
  • 16 Jan 2013 Preclinical trials in Autoimmune disorders in USA (Parenteral)
  • 12 Nov 2012 Alnylam Pharmaceuticals and Tekmira Pharmaceuticals Corporation sign a new licensing agreement regarding RNAi-based therapies, superseding all previous agreements, and resolve all litigation
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top